ATP8B1

Across TCGA pan-cancer cohorts, ATP8B1 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated ATP8B1 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ATP8B1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP8B1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, KIRC, and UCEC are the cancer types where ATP8B1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	All	0.110	0.640	<.001	39	view →
KIRC	OS	Median	All	0.154	0.883	<.001	33	view →
UCEC	DFS	Median	All	0.974	0.618	.002	32	view →
BLCA	OS	Median	IV	0.121	0.610	<.001	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
LUSC	DFS	Median	II,III,IV	0.185	0.709	.018	3	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ATP8B1–SCLC (DFS)

Open the SCLC breakdown →